HAVCR2 and neoplasm: Furthermore, the release of HMGB1 by dying tumor cells was shown to compete with nucleic acid binding to the receptor TIM3 selectively expressed by intratumoral DCs with consequent inhibition of anti-tumor immune responses [95].